Results for "search term"

Partnerships

Why Partner With Us?

As part of our ongoing commitment to excellence and innovation, we’ve joined forces with several outstanding biotech organizations, both locally in the SF Bay Area and across the country. These strategic partnerships have allowed both Antibody Solutions and our collaborators to work effectively on: 

Asset 1 (2)

Human Transgenic Animal Providers

Alloy-Therapeutics-logo

Alloy Therapeutics

Alloy Therapeutics has developed several strains of immunocompetent transgenic mice, allowing for best-in-class in vivo human antibody technology, and offers it for diverse and non-exclusive use.

OmniAbLogo

OmniAb®

OmniAb® provides therapeutic antibody platforms that produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity.

Leveragen

Leveragen has developed a next-generation fully human single-domain antibody model, the Singularity Sapiens Mouse, which exclusively generates heavy-chain antibodies from the complete human VH repertoire integrated into the mouse Igh locus. This targeted approach ensures the faithful expression of human immunoglobulin genes, eliminates interfering conventional antibodies, and promotes optimal B cell development and robust immune responses.

 

AbTherx Atlas™ Mouse Technologies

Atlas™ Mouse Technologies from AbTherx feature three models – the Full Human Diversity Mouse, Binary Fixed Light Chain Mouse, and Long CDR3 Mouse – that give antibody discovery teams novel approaches to address some of the challenges inherent in traditional transgenic platforms, including royalty- and milestone-free licensing options

Hugo-Ab_logo_R

Cyagen HUGO-Ab™ Mouse Models: HUmanized Genomic Ortholog for Antibody Development

Cyagen’s HUGO-Ab™ Mouse Models leverage the company’s proprietary TurboKnockout® ESC-mediated gene targeting to humanize the VH and VL genes in situ, offering more stable phenotypic and functional outcomes than traditional transgenic methods, and substitute an up-front payment for royalties and/or milestone payments.

Strategic Partners

Single Cell Technology

Single Cell Technology

Single Cell Technology, Inc. (SCT) has developed the pioneering AbTHENEUM™ platform to rapidly and efficiently screen antibodies and mRNA against multiple molecules to measure their affinity and specificity.

mAbsolve-logo-coloured-1

mAbsolve

mAbsolve has developed the premier Fc silencing mutation available on the broad market. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs.

In each case, we are happy to share our passion for science and our commitment to helping biopharmaceutical companies solve their most pressing research challenges.

Partnering with Antibody Solutions creates opportunities for innovation without sacrificing your time or inflating your budget. We welcome the chance to explore opportunities for advancing your antibody research together.

Let's Start the Conversation